Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials-Reference-Cited by-同舟云学术

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

Published:2016-08-24 Issue:10 Volume:18 Page:1034-1040
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Salsali A.¹,Kim G.²,Woerle H. J.²,Broedl U. C.²,Hantel S.³

Affiliation:

1. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield Connecticut USA

2. Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany

3. Boehringer Ingelheim Pharma GmbH Biberach Germany

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12734

Reference20 articles.

1. Standards of medical care in diabetes–2015;American Diabetes Association;Diabetes Care,2015

2. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

3. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

4. Boehringer Ingelheim.Jardiance® (empagliflozin) tablets prescribing information.2015.http://bidocs.boehringer‐ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf. Accessed June 12 2015.

5. Boehringer Ingelheim.Jardiance® (empagliflozin) summary of product characteristics.2015.http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002677/human_med_001764.jsp&mid=WC0b01ac058001d124. Accessed June 12 2015.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

2. Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD;Kidney International Reports;2023-11

3. Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF;International Journal of Molecular Sciences;2022-09-09

4. Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations;Journal of Diabetes;2022-04-17

5. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease;Drugs;2021-08-07